Evidence overview
Collagen
Collagen supplementation is one of the fastest-growing consumer supplement categories, with a research base concentrated on skin aging, joint and osteoarthritis symptoms, and musculoskeletal performance/recovery. The evidence is mixed: some indications have meta-analytic synthesis, but methodological limitations - including industry funding influence and short trial durations - are unusually prominent in this literature. Most products use hydrolyzed peptides from bovine, marine, or porcine sources.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Most abundant protein in the human body; main structural protein in skin, bone, cartilage,...
Study coverage
Study coverage by goal
PubMed counts for Collagen grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Collagen.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Collagen is the most abundant protein in the human body and the main structural protein in skin, bone, cartilage, tendon, and other connective tissues. Supplemental collagen products (hydrolyzed collagen peptides from bovine, marine, or porcine sources) are studied across skin aging and dermatologic outcomes, joint symptoms and osteoarthritis, athletic performance and tendon/ligament outcomes, post-surgical recovery, and bone density. Multiple collagen types exist (Type I dominates skin and bone; Type II dominates cartilage; Type III is found in skin and blood vessels); supplements vary in type composition based on source material.
The outcome dimensions covered most heavily are skin aging (including skin elasticity, wrinkles, and hydration - the most-marketed consumer use), knee osteoarthritis symptoms (with recent meta-analytic synthesis), musculoskeletal performance and tendon/ligament outcomes in combination with physical training, bone density (smaller and more contested), and wound healing in clinical contexts. Methodological limitations are unusually prominent in this literature: many trials are short (8-12 weeks), industry-funded, and use proprietary peptide formulations whose specific composition is not fully disclosed. Recent meta-analyses have begun explicitly assessing funding influence on reported outcomes.
Demographically, the skin-aging literature concentrates on women over 35 (the marketing-target demographic); the osteoarthritis literature on adults with knee OA; the athletic-performance literature on younger adults engaged in regular training. Source variation matters: marine collagen (smaller peptide profile, often Type I) is positioned differently from bovine (mixed Type I and III) and porcine sources. Proprietary peptide formulations (Verisol, Naticol, Fortigel, BodyBalance, and others) have specific research bases that complicate generic claims about 'collagen supplementation' as a category.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Collagen is generally well-tolerated. The most-common adverse effects are mild gastrointestinal discomfort, fullness, and occasional aftertaste (more common with marine-derived products). Allergic reactions are rare but possible, particularly in individuals with fish, shellfish, or egg allergies depending on the source. No tolerable upper limit has been established. Drug interactions are minimal at typical supplemental doses; collagen is a protein source providing amino acids including glycine, proline, and hydroxyproline. People with phenylketonuria should be aware that some products contain added phenylalanine, and those with known allergies to specific protein sources should check labeling carefully. Collagen is an incomplete protein (low in essential amino acids like tryptophan), so it should not replace high-quality dietary protein for general nutrition.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Recent meta-analysis on collagen for skin aging that specifically examines industry funding influence on reported outcomes. The methodologically sophisticated reference for the supplement's most-marketed use, distinguishing trials by funding source and quality.
View on PubMedMost-recent comprehensive synthesis of collagen for knee osteoarthritis, the supplement's second-major research stream and an area with growing clinical interest beyond the consumer-cosmetic market.
View on PubMedSystematic review on collagen plus long-term physical training across musculotendinous outcomes, functional recovery, and body composition - the third-major research stream for the supplement, particularly relevant to athletic and recovery use cases.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the collagen literature at a general level. It does not address which collagen type and source (marine vs. bovine vs. porcine; Type I vs. II vs. combinations) is right for your specific goal, what proprietary peptide formulation has the most-relevant evidence for your case, what dose to use (which varies substantially across products and indications), or how collagen fits with your dietary protein intake. The proliferation of brand-specific peptide formulations makes the personalized report especially useful for navigating this market.
Personalized to you
Get a personalized Collagen report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Collagen materially updates. No account required.